PubMed Health⌕ Search

Biomedical subjects

E Rinne

Publications and source records attributed to E Rinne.

4 recordsLinked to original sources

Bacteria in ulcera crurum.

Bacterial cultures derived from 432 chronic leg ulcers were analysed retrospectively to determine which bacteria are most commonly found in these ulcers. The study covered a 2-year period. Two-thirds of the patients were over 70 years of age. Staphylococcus aureus was found in nearly half of the ulcers studied, Pseudomonas sp. in one-third, pyogenic streptococci and enterococci in every fifth and Proteus sp. in every tenth. The frequency by which pyogenic streptococci were isolated was about 10 to 20 times as high as previously reported. Obligate anaerobic bacteria were also frequently isolated. The sensitivity of the isolates from the second year to antimicrobial agents likely to be chosen if systemic therapy were required is also reported. The results are discussed in relation to previous findings.

Aged↗

Bacteria isolated from skin and soft tissue lesions.

The pathogens most often isolated from lesions in skin and soft tissues were Staphylococcus aureus and Streptococcus pyogenes. Cultures from venous leg ulcers, decubitus ulcers and infectious gangrene often yielded also Pseudomonas spp., enterobacteria and enterococci. Obligate anaerobes were frequently isolated especially from abscesses and decubitus ulcers. One third of the abscesses and half of the decubitus ulcers yielded obligate anaerobes.

Abscess↗

Efficacy of interferon and placebo in the treatment of recurrent genital herpes: a double-blind trial.

One hundred patients experiencing recurrence of genital herpes were randomly assigned to treatment with either recombinant DNA-derived human leukocyte interferon (interferon alfa-2a, Roferon-A, Hoffmann-LaRoche & Co., Ltd.) or placebo in a double-blind study. All patients were given a three-day course of treatment by subcutaneous injection within 24 hr after the first signs of recurrence. Interferon alfa-2a was given according to one of two daily regimens (6 X 10(6) or 18 X 10(6) units), either as a single dose followed by two doses of placebo or as three consecutive doses. In comparison with placebo, interferon alfa-2a reduced the duration of a single recurrent episode of genital herpes by approximately 50% (P less than .05) compared with placebo. As compared with pretreatment episodes, a reduction of greater than 50% in healing time was observed in 81% of those receiving interferon alfa-2a in comparison with only 10% of placebo recipients. Response was not related to size of dose, and treatment did not significantly prolong the interval between the first and second recurrences. No serious adverse reactions were observed, but most patients developed flu-like symptoms after the subcutaneous injection. Leukopenia and thrombocytopenia were minimal and transient. On the basis of overall efficacy and adverse effects, the single dose of 6 X 10(6) units of interferon alfa-2a was considered optimal, and this regimen may be of value in the routine treatment of recurrent herpes.

Adult↗